Positive CHMP Opinion for Trastuzumab Biosimilar Herzuma®
On 14th December 2017 our business partner Celltrion received the positive opinion for Herzuma® (trastuzumab biosimilar) from EMA´s CHMP for early breast cancer, metastatic breast cancer, and metastatic gastric cancer. More information can be found here. Read more .
Innovationsreport 2017
In the recent "Innovation Report 2017" published by Prof. Dr. Gerd Glaeske, University of Bremen and Prof. Wolf-Dieter Ludwig, Chairman of the Drug Commission of the German Medical Profession, a special chapter focuses on the topic of "Biosimilars in oncology". Read more here.
Pharmaboardroom Interview
Check out the new interview with Dr. Sabine Möritz-Kaisergruber and Mag. Helmut Kaisergruber at Pharmaboardroom.com. They are talking about Astro Pharma development, our vision and strategy: here..
Danish Switching Study
In the so called DANBIO registry study, the switch from Remicade to Remsima due to non-medical reasons was investigated in a total of 802 patients with rheumatoid arthritis, psoriasis arthritis and ankylosing spondylitis. The patients were treated with Infliximab for a median of already over 6 years. The switch to Remsima... Read more here..
NorSwitch study
The results of the NorSwitch study (a switching study to Infliximab biosimilar) confirm the safety for patients... Read more here.
New information booklet on Biosimilars.
The following link leads to the new information booklet on biosimilars, developed by EMA and European Committee... Read more here.
Austria pro Moldavia
Just like last year, Astro Pharma again supported the aid trips of Dr Euler-Rolle in 2016 with generous donations of drugs. Twice a year, Dr Euler-Rolle and his assistants bring aid shipments to families and hospitals in Romania and Moldova. We are committed to supporting this project whenever possible. You can read more under "Austria pro Moldavia".
Biosimilars - Hurdles and Ways to Success
On Thursday, 23.3.2017 Dr. Sabine Möritz-Kaisergruber, President of the Biosimilars Association, was invited to the 2-day IIR-conference, which took place under the title "Biosimilars - Acceptance in the Clinic / Reimbursement situation / Legal framework/ Pricing". The title of her presentation was "Biosimilars - Hurdles and Ways to Success". Read more here.
Importance of biosimilars in oncology
In its latest position paper of January 2017, the European Society for Medical Oncology (ESMO) stresses the importance of biosimilars for the sustainable financing of cancer therapies (Tabernero et al., 2017). Read more here.
Information for patients on Biosimilars 2016
This edition of information for patients on biosimilars was prepared jointly by representatives of the European Medicines Agency (EMA), the European Commission and corresponding third parties. Read more about this here.
Our international
network
Our international network
Products
Astropharma Products
Our Company
Astropharma our Company
Astro Pharma

Astro Pharma is a family-run business from Austria and consists of 30 pharmaceutical professionals who know the Austrian market like no other. We specialise in innovative and economical drugs and niche products which are indispensable for the health system of the future and can take the strain off it permanently. We offer our own products such as antibiotics and vaccines and are general agents in Austria for international drug companies. An international network combined with unique local knowledge prepare us for any challenge: With our outstanding service and product range, we start where others reach their limits

Biosimilarsverband
Sales of biosimilars

Astro Pharma is a founding member of the Austrian Biosimilar Association (BiVÖ). Astro Pharma and other members of the Association, A-med GmbH, ratiopharm Arzneimittel Vertriebs GmbH, Sandoz GmbH and STADA Arzneimittel GmbH, account for more than 85% of the Austrian biosimilar market. The president of the voluntary lobby group of biosimilar providers and producers is Sabine Möritz-Kaisergruber, Managing Partner of Astro Pharma. The Austrian Biosimilar Association was founded in 2016 and is committed to providing the best care for Austrian patients with top-quality biopharmaceutical drugs at affordable prices. Biosimilars are biological drugs which can significantly take the strain off the healthcare system because of their consistent quality, safety and effectiveness. For more information about the Austrian Biosimilar Association, please visit: www.biosimilarsverband.at

More information: www.biosimilarsverband.at

biosimilarsverband